Validation Data Gallery
Tested Applications
| Positive FC detected in | human PBMCs |
Recommended dilution
| Application | Dilution |
|---|---|
| This reagent has been pre-titrated and tested for flow cytometric analysis. The suggested use of this reagent is 5 ul per 10^6 cells in a 100 µl suspension or 5 ul per 100 µl of whole blood. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
CL594-98174 targets CD99 in FC applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Recombinant |
| Type | Antibody |
| Immunogen | Recombinant Protein 相同性解析による交差性が予測される生物種 |
| Full Name | CD99 molecule |
| Calculated molecular weight | 19 kDa, 16 kDa, 17 kDa |
| GenBank accession number | BC021620 |
| Gene Symbol | CD99 |
| Gene ID (NCBI) | 4267 |
| Conjugate | CoraLite®594 Fluorescent Dye |
| Excitation/Emission maxima wavelengths | 588 nm / 604 nm |
| Form | Liquid |
| Purification Method | Protein A purification |
| UNIPROT ID | P14209 |
| Storage Buffer | PBS with 0.09% sodium azide and 0.5% BSA , pH 7.3 |
| Storage Conditions | Store at 2-8°C. Avoid exposure to light. Stable for one year after shipment. |
Background Information
CD99, also known as MIC2, is a heavily O-glycosylated transmembrane protein involved in T-cell adhesion processes and in spontaneous rosette formation with erythrocytes. CD99 is broadly distributed on many cell types, with particularly strong expression on human cortical thymocytes, Ewing's sarcoma cells and peripheral primitive neuroectodermal tumors (PMID: 9794396; 16984917). In normal cells, CD99 has been functionally implicated in cell adhesion, migration, apoptosis, differentiation, activation, and proliferation of lymphocytes and monocyte extravasation and transport of several transmembrane proteins (PMID: 16984917).
Protocols
| Product Specific Protocols | |
|---|---|
| FC protocol for CL594 CD99 antibody CL594-98174 | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |